Compare LION & MIRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LION | MIRM |
|---|---|---|
| Founded | 1997 | 2018 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Movies/Entertainment | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.5B | 5.7B |
| IPO Year | 2025 | 2019 |
| Metric | LION | MIRM |
|---|---|---|
| Price | $14.81 | $99.02 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 13 |
| Target Price | $11.89 | ★ $119.85 |
| AVG Volume (30 Days) | ★ 3.5M | 966.1K |
| Earning Date | 05-21-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 74.59 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $3,195,500,000.00 | $19,138,000.00 |
| Revenue This Year | N/A | $26.22 |
| Revenue Next Year | $22.98 | $22.04 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 7.00 | N/A |
| 52 Week Low | $5.65 | $43.40 |
| 52 Week High | $13.03 | $114.99 |
| Indicator | LION | MIRM |
|---|---|---|
| Relative Strength Index (RSI) | 80.07 | 48.48 |
| Support Level | $6.26 | $97.49 |
| Resistance Level | N/A | $107.51 |
| Average True Range (ATR) | 0.53 | 6.02 |
| MACD | 0.08 | -1.04 |
| Stochastic Oscillator | 98.48 | 23.44 |
Lionsgate Studios Corp is a motion picture and television studio operations aligned with the STARZ premium subscription platform to bring a varied portfolio of entertainment to consumers around the world. The group has two reportable business segments: the Motion Picture and Television Production reportable segments. Motion Picture consists of the development and production of feature films, the acquisition of North American and world-wide distribution rights. Television Production consists of the development, production, and world-wide distribution of television productions, including television series, television movies and mini-series, and non-fiction programming.
Mirum Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare and orphan diseases. Its main product, Livmarli (maralixibat), is an orally administered IBAT inhibitor approved to treat cholestatic pruritus in patients with Alagille syndrome. The company is also developing treatments such as maralixibat for PFIC and ALGS, and volixibat for adult cholestatic liver diseases. Mirum currently has three approved medicines: Livmarli, Cholbam, and Ctexli.